Research Projects

The need: Today, although over 6M people suffer from Parkinson's and related diseases worldwide we have no objective early diagnostic test. By the time patients present the symptoms that lead to diagnosis the disease is already very advanced and the options for treatment extremely limited. This has an enormous impact on cost of care and an even...

Dementia affects around 50 M people globally (mainly over 65 years old) and has high associated costs (~ $1 trillion per year). 60%-80% cases correspond to Alzheimer’s Disease (AD), which is expected to continue increasing exponentially in the next decades. At present, there are several disease-modifying treatments for AD in development, but once...

To the date there is no accurate scale to quantitatively measure motor dysfunction in neurological movement disorders. Doctors heavily relay on the information provided by the patients themselves. Objective data concerning the patient’s actual movements or seizures during their ordinary day would be very valuable for the doctors. The current common...

Studies reported that bilingualism strengths executive functions in elderly and delays the Alzheimer’s disease (AD) onset for five years. These findings suggest that bilingualism enhances the cognitive reserve (CR). CR is a construct that includes a set of cognitively stimulating experiences (e.g. high education level, high occupational status)...

NEKI is a technological company created by seasoned entrepreneurs from different fields like Programming, Marketing and Management. We brought our expertise to this company in order to implement advanced safety solutions for person location and real time communication to relatives or health professionals. Alzheimer and other cognitive impairments...

Imaging of distribution of drugs in mice delivers accurate information for confirmation that the mechanism of action elaborated in cell-based assays is also operative in vivo. These data are critical for the transfer of drug discovery process from pre-clinical to clinical phase. To enable the imaging, drugs should be labeled with easily detectable...

Europe faces an enormous human toll of brain disorders, with an estimated 83 million people affected, and economic costs amounting to approximately €800 billion. Drug treatments for brain disorders prove often less than effective with a lack of selective cell targeting. A failure to develop new drugs has led major Pharmaceutical companies to...

Alzheimer's disease (AD) is a major medical problem and is currently an issue of global general interest as the total number of people with dementia is projected to reach ~80M in 2030 and almost duplicating this number by 2050. The lack of an efficient and affordable solution in the AD's health care sector has motivated our company Alzohis to...

Modern network science has introduced exciting new opportunities for understanding the brain as a complex system of interacting units in both health and disease and across the human lifespan. Despite the rapidly growing interdisciplinary science of complex networks, which spans the range from genetic and metabolic networks all the way up to social...

Bio2Brain aims to create a trans-European network of industrially oriented specialists fully trained and experienced, a significant driving force in innovating novel technologies to deliver biopharmaceuticals safely and via the nasal route of administration to the central nervous system (CNS). Diseases of the CNS and the spinal cord affect around...

Spider silk is Nature’s high performance material that has the potential to revolutionize the materials industry. However, production and spinning of artificial spider silk fibers are challenging, and current methods to produce silk fibers include denaturing conditions which prevent the silk proteins from assembling into fibers in the same complex...

The objective of this project is to develop a business plan for the continued clinical development and commercialisation of ALZ-101 – a novel therapeutic Alzheimer´s disease (AD) vaccine candidate designed to prevent neurodegeneration in the brain. AD is a therapeutic area in dire need of effective treatments. The disease, which primarily afflicts...